Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) announced its participation in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-15, 2021. The event will feature an on-demand presentation and one-on-one meetings with Chief Financial Officer Gilad Mamlok. The presentation becomes available on September 13 at 7 a.m. ET. Sol-Gel specializes in developing topical drug products for skin diseases, including FDA-approved TWYNEO for acne treatment. Their pipeline includes EPSOLAY for rosacea, with a pending NDA, as well as candidates SGT-210, SGT-310, and SGT-510 for various skin conditions.

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in H.C. Wainwright’s 23^rd Global Investment Conference.

H.C. Wainwright 23rd Annual Global Investment Conference (September 13 – 15, 2021)
Format	On demand presentation and 1-on-1 meetings
Speaker:	Gilad Mamlok, Chief Financial Officer
Date:	September 13-15
Time:	Presentation available on demand beginning Monday, September 13th 7 a.m. ET
To Listen	Register here; a replay will be archived for 90 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section)

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.

The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.

For additional information, please visit www.sol-gel.com.

Contact:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1-917-734-7387

Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com

FAQ

When is Sol-Gel Technologies participating in the H.C. Wainwright Conference?

Sol-Gel Technologies will participate in the H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-15, 2021.

Who is the speaker representing Sol-Gel Technologies at the conference?

Gilad Mamlok, the Chief Financial Officer, will represent Sol-Gel Technologies at the conference.

What will Sol-Gel present at the H.C. Wainwright Conference?

Sol-Gel will present an on-demand presentation starting September 13, 2021, at 7 a.m. ET.

What are the key products of Sol-Gel Technologies?

Key products include TWYNEO for acne treatment and EPSOLAY for rosacea, with the latter's NDA filed with the FDA.

How can I access Sol-Gel Technologies' presentation?

The presentation can be accessed on demand by registering on their website and will be available for replay for 90 days.